AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10928668 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 81
Study 8641482 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian cauterization
Number of subjects: 17
Study 8641482 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone agonist (GnRH-a) and oral contraceptive (OC) therapy
Number of subjects: 17
Study 1434782 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure PEP-mask physiotherapy (PEP)
Number of subjects: 14
Study 1434782 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP followed by AD (PEP-AD)
Number of subjects: 14
Study 1434782 — intervention group
Group type: EXPERIMENTAL
Intervention: AD followed by PEP (AD-PEP)
Number of subjects: 14
Study 1434782 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic drainage (AD)
Number of subjects: 14
Study 1434782 — intervention group
Group type: COMPARATOR
Intervention: No PT except for spontaneous coughing
Number of subjects: 14
Study 3902531 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 1000 mg once daily
Number of subjects: 75
Study 3902531 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg once daily
Number of subjects: 75
Study 31096945 — intervention group
Group type: EXPERIMENTAL
Intervention: OMNIgene®•SPUTUM (OM-S) medium
Number of subjects: 362
Study 31096945 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC; cold-chain transported samples)
Number of subjects: 362
Study 29384450 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the ventral striatal area
Number of subjects: 10
Study 29384450 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS ON
Number of subjects: 10
Study 29384450 — intervention group
Group type: COMPARATOR
Intervention: DBS OFF
Number of subjects: 10
Study 28077163 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline and behavioral support
Number of subjects: 510
Study 28077163 — intervention group
Group type: COMPARATOR
Intervention: Placebo and behavioral support
Number of subjects: 510
Study 27530008 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Harvard's step test (VO₂max)
Number of subjects: 300
Study 27530008 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic fitness (VO₂max)
Number of subjects: 300
Study 23219537 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg avanafil
Number of subjects: 298
Study 23219537 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg avanafil
Number of subjects: 298
Study 23219537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 20447774 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (62 Gy in 20 fractions within 5 weeks, 4 fractions/wk)
Number of subjects: 168
Study 20447774 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy (80 Gy in 40 fractions within 8 weeks)
Number of subjects: 168
Study 20447774 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Number of subjects: 168
Study 20447774 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy
Number of subjects: 168
Study 19081791 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP+AZT+ddI (Group A)
Number of subjects: 198
Study 19081791 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP+3TC+d4T (Group B)
Number of subjects: 198
Study 19081791 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP+AZT+3TC (Group C)
Number of subjects: 198
Study 19081791 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV‐Ab positive patients with CD4 count >250/ul
Number of subjects: 198
Study 17007488 — intervention group
Group type: EXPERIMENTAL
Intervention: V.A.C. Therapy
Number of subjects: 0
Study 15074447 — intervention group
Group type: EXPERIMENTAL
Intervention: Kuwaiti subjects walking at 'free' speed
Number of subjects: 30
Study 15074447 — intervention group
Group type: EXPERIMENTAL
Intervention: Kuwaiti subjects walking at 'slow' speed
Number of subjects: 30
Study 15074447 — intervention group
Group type: EXPERIMENTAL
Intervention: Kuwaiti subjects walking at 'fast' speed
Number of subjects: 30
Study 15074447 — intervention group
Group type: COMPARATOR
Intervention: Swedish subjects (control group)
Number of subjects: 30
Study 10977030 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin powder (87.2 U)
Number of subjects: 13
Study 10977030 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin (10.2 U)
Number of subjects: 13
Study 10977030 — intervention group
Group type: COMPARATOR
Intervention: Intravenous insulin (5.5 U)
Number of subjects: 13
Study 9058683 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef (raw, medium, and well-cooked)
Number of subjects: 335
Study 9058683 — intervention group
Group type: COMPARATOR
Intervention: DBPCFC (double-blind placebo-controlled food challenges)
Number of subjects: 335
Study 9058683 — intervention group
Group type: EXPERIMENTAL
Intervention: SDS-PAGE analysis of beef extracts
Number of subjects: 335
Study 9058683 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE binding analysis
Number of subjects: 335
Study 8485067 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 10 mg bid
Number of subjects: 20
Study 8485067 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 20 mg bid
Number of subjects: 20
Study 8485067 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg bid
Number of subjects: 20
Study 3959099 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective measurement
Number of subjects: 23
Study 3959099 — intervention group
Group type: COMPARATOR
Intervention: Ongoing daily self-monitoring
Number of subjects: 23
Study 3959099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-affective changes
Number of subjects: 23
Study 3959099 — intervention group
Group type: COMPARATOR
Intervention: Behavioral changes
Number of subjects: 23
Study 3959099 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic gains at follow-up
Number of subjects: 23
Study 3959099 — intervention group
Group type: EXPERIMENTAL
Intervention: Female partners
Number of subjects: 23
Study 28654629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 0
Study 28654629 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 0
Study 28654629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab or Bevacizumab (retreatment criteria not met)
Number of subjects: 0
Study 28654629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab or Bevacizumab
Number of subjects: 0
Study 27450670 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined LL and OS restoration within 5mm
Number of subjects: 60
Study 27450670 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait symmetry
Number of subjects: 60
Study 27450670 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical scores
Number of subjects: 60
Study 24311644 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 1125 mg
Number of subjects: 52
Study 24311644 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB) 294 mg
Number of subjects: 52
Study 23072834 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (0.5 mg/day for first 3 days, then 1 mg/day for 4 days)
Number of subjects: 38
Study 23072834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 21958943 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/NETA (estradiol 2 mg/norethisterone acetate 1 mg)
Number of subjects: 154
Study 21958943 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg)
Number of subjects: 154
Study 21958943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 21958943 — intervention group
Group type: COMPARATOR
Intervention: Black cohosh
Number of subjects: 154
Study 18434919 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment for pediatric major depressive disorder
Number of subjects: 146
Study 18434919 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal depressive symptoms
Number of subjects: 146
Study 18434919 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal depressive symptoms at baseline
Number of subjects: 146
Study 16254428 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine treatment
Number of subjects: 202
Study 14605511 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin extended release/lovastatin
Number of subjects: 0
Study 14605511 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 0
Study 14605511 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 0
Study 10717926 — intervention group
Group type: EXPERIMENTAL
Intervention: Vobenzim (initial dose 18‐24 dragees, maintenance 12‐15 dragees a day)
Number of subjects: 174
Study 10717926 — intervention group
Group type: COMPARATOR
Intervention: Pathogenetic therapy only (Control)
Number of subjects: 174
Study 9175023 — intervention group
Group type: EXPERIMENTAL
Intervention: CD29 density on CD8+ cells
Number of subjects: 28
Study 8263606 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber diet (31.3 g fiber/d, 586 mg calcium/d)
Number of subjects: 7
Study 8263606 — intervention group
Group type: COMPARATOR
Intervention: Low fiber diet (6.5 g fiber/d, 530 mg calcium/d)
Number of subjects: 7
Study 8263606 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber diet
Number of subjects: 7
Study 8263606 — intervention group
Group type: COMPARATOR
Intervention: Low fiber diet
Number of subjects: 7
Study 3744131 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (5,000 antifactor Xa U/24 h)
Number of subjects: 432
Study 3744131 — intervention group
Group type: COMPARATOR
Intervention: Low-dose conventional heparin (5,000 IU/12 h)
Number of subjects: 432
Study 29966193 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized music playlists based on personal preferences
Number of subjects: 99
Study 27255275 — intervention group
Group type: EXPERIMENTAL
Intervention: Peru (post-ratification of FTA)
Number of subjects: 0
Study 27255275 — intervention group
Group type: EXPERIMENTAL
Intervention: Peru (pre/post enforcement of FTA)
Number of subjects: 0
Study 27255275 — intervention group
Group type: COMPARATOR
Intervention: Bolivia (control)
Number of subjects: 0
Study 24121658 — intervention group
Group type: EXPERIMENTAL
Intervention: G.O.A.L. intervention (90-min after-school physical activity club 4 days/week and one motivational interviewing session with a registered nurse)
Number of subjects: 30
Study 24121658 — intervention group
Group type: EXPERIMENTAL
Intervention: G.O.A.L. intervention
Number of subjects: 30
Study 24121658 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing session with a registered nurse
Number of subjects: 30
Study 22329471 — intervention group
Group type: EXPERIMENTAL
Intervention: ARI + LTG
Number of subjects: 351
Study 22329471 — intervention group
Group type: COMPARATOR
Intervention: PBO + LTG
Number of subjects: 351
Study 20142219 — intervention group
Group type: EXPERIMENTAL
Intervention: Misago nitinol stent implantation
Number of subjects: 55
Study 17943490 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week heavy resistance strength-training program
Number of subjects: 0
Study 17943490 — intervention group
Group type: COMPARATOR
Intervention: Neural approach (as a comparison)
Number of subjects: 0
Study 20397590 — intervention group
Group type: EXPERIMENTAL
Intervention: Counter-stereotypic images (female scientists)
Number of subjects: 100
Study 20397590 — intervention group
Group type: COMPARATOR
Intervention: Stereotypic images (male scientists)
Number of subjects: 100
Study 15723201 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 100% tea tree oil (TTO)
Number of subjects: 0
Study 15723201 — intervention group
Group type: COMPARATOR
Intervention: Topical application of 5% TTO lotion
Number of subjects: 0
Study 15723201 — intervention group
Group type: COMPARATOR
Intervention: Topical application of placebo lotion (no TTO)
Number of subjects: 0
Study 15723201 — intervention group
Group type: COMPARATOR
Intervention: Topical application of 100% macadamia oil
Number of subjects: 0
Study 15723201 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 100% TTO
Number of subjects: 0
Study 11772797 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg midazolam syrup
Number of subjects: 95
Study 11772797 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg midazolam syrup
Number of subjects: 95
Study 11772797 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg midazolam syrup
Number of subjects: 95
Study 11772797 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg midazolam syrup (maximum 20 mg)
Number of subjects: 95
Study 11772797 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of midazolam syrup
Number of subjects: 95
Study 9674809 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. methylprednisolone high dose
Number of subjects: 108
Study 9674809 — intervention group
Group type: COMPARATOR
Intervention: i.v. methylprednisolone low dose
Number of subjects: 108
Study 7988623 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 10 mg
Number of subjects: 64
Study 7988623 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 64
Study 7988623 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg + 250 mg) + Midazolam 10 mg
Number of subjects: 64
Study 7988623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 7988623 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 750 mg (as a positive control)
Number of subjects: 64
Study 3052965 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen 10 mg/kg/day
Number of subjects: 28
Study 3052965 — intervention group
Group type: EXPERIMENTAL
Intervention: tolmetin 25 mg/kg/day
Number of subjects: 28
Study 3052965 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac 2 mg/kg/day
Number of subjects: 28
Study 3052965 — intervention group
Group type: COMPARATOR
Intervention: naproxen
Number of subjects: 28
Study 3052965 — intervention group
Group type: COMPARATOR
Intervention: tolmetin
Number of subjects: 28
Study 3052965 — intervention group
Group type: COMPARATOR
Intervention: diclofenac
Number of subjects: 28
Study 31376878 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo preconditioning in the morning (08:00-10:00) with high endogenous cortisol levels
Number of subjects: 77
Study 31376878 — intervention group
Group type: COMPARATOR
Intervention: Placebo preconditioning in the afternoon (16:00-18:00) with low endogenous cortisol levels
Number of subjects: 77
Study 30384842 — intervention group
Group type: EXPERIMENTAL
Intervention: iv exenatide (1‐h bolus of 0.05 µg min‐1 followed by a constant infusion of 0.025 µg min‐1)
Number of subjects: 92
Study 30384842 — intervention group
Group type: EXPERIMENTAL
Intervention: iv exenatide
Number of subjects: 92
Study 30384842 — intervention group
Group type: COMPARATOR
Intervention: iv insulin therapy (control group)
Number of subjects: 92
Study 27368117 — intervention group
Group type: EXPERIMENTAL
Intervention: SB3
Number of subjects: 109
Study 27368117 — intervention group
Group type: COMPARATOR
Intervention: EU trastuzumab
Number of subjects: 109
Study 27368117 — intervention group
Group type: COMPARATOR
Intervention: US trastuzumab
Number of subjects: 109
Study 27368117 — intervention group
Group type: EXPERIMENTAL
Intervention: SB3, EU trastuzumab, US trastuzumab
Number of subjects: 109
Study 24274806 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored interventions (specific details on dosage and duration not provided)
Number of subjects: 9077
Study 24274806 — intervention group
Group type: COMPARATOR
Intervention: Control condition (specific details not provided)
Number of subjects: 9077
Study 24274806 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored interventions
Number of subjects: 9077
Study 21673137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 450 µg/d
Number of subjects: 44
Study 21673137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 900 µg/d
Number of subjects: 44
Study 21673137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 1350 µg/d
Number of subjects: 44
Study 21673137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 1800 µg/d
Number of subjects: 44
Study 21673137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 2250 µg/d
Number of subjects: 44
Study 21673137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 2025 µg/d
Number of subjects: 44
Study 21673137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide infusion
Number of subjects: 44
Study 21165861 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazard nature image category
Number of subjects: 109
Study 21165861 — intervention group
Group type: COMPARATOR
Intervention: Other image categories (prospect, refuge, mixed prospect and refuge)
Number of subjects: 109
Study 17497983 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery
Number of subjects: 160
Study 17497983 — intervention group
Group type: EXPERIMENTAL
Intervention: Scissors for dissection and ligatures for haemostasis
Number of subjects: 160
Study 17497983 — intervention group
Group type: COMPARATOR
Intervention: Suction drain
Number of subjects: 160
Study 17497983 — intervention group
Group type: COMPARATOR
Intervention: Corrugated drains
Number of subjects: 160
Study 16113179 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide as a slow intravenous infusion over 15 minutes (SIG group)
Number of subjects: 300
Study 16113179 — intervention group
Group type: COMPARATOR
Intervention: 10 mg metoclopramide intravenous bolus infusion over two minutes (BIG group)
Number of subjects: 300
Study 12107041 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 248
Study 12107041 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate plus minimal intervention (3‐weekly sessions of 20 min)
Number of subjects: 248
Study 12107041 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate plus brief cognitive behavioural therapy (7‐weekly sessions of 60 min)
Number of subjects: 248
Study 12107041 — intervention group
Group type: COMPARATOR
Intervention: Control group (Acamprosate only)
Number of subjects: 248
Study 12107041 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 248
Study 10414418 — intervention group
Group type: EXPERIMENTAL
Intervention: Toluene diisocyanate (TDI) exposure (5 ppb for 6 h followed by 20 ppb for 20 min)
Number of subjects: 17
Study 10414418 — intervention group
Group type: EXPERIMENTAL
Intervention: Toluene diisocyanate (TDI) exposure
Number of subjects: 17
Study 10414418 — intervention group
Group type: COMPARATOR
Intervention: Ambient air exposure
Number of subjects: 17
Study 7669711 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/FA (5-fluorouracil plus folinic acid)
Number of subjects: 149
Study 7669711 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU/FA/IFN (5-fluorouracil plus folinic acid plus interferon-alpha)
Number of subjects: 149
Study 7669711 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU/FA/IFN
Number of subjects: 149
Study 7669711 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/FA
Number of subjects: 149
Study 2129490 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg famotidine b.d.
Number of subjects: 18
Study 2129490 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg naproxen b.d. + 20 mg famotidine b.d.
Number of subjects: 18
Study 2129490 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg naproxen b.d. + 40 mg famotidine nocte
Number of subjects: 18
Study 2129490 — intervention group
Group type: COMPARATOR
Intervention: 500 mg naproxen b.d. + placebo
Number of subjects: 18
Study 2129490 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment periods
Number of subjects: 18
Study 6160364 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma Venin 10 g within the first 48 h after surgery
Number of subjects: 100
Study 6160364 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Gamma Venin)
Number of subjects: 100
Study 31842966 — intervention group
Group type: EXPERIMENTAL
Intervention: Small stitches closure followed by augmentation with a light-weight polypropylene mesh in the onlay technique
Number of subjects: 812
Study 31842966 — intervention group
Group type: COMPARATOR
Intervention: Closure of the midline incision with a slowly absorbable monofilament suture in the small stitches technique
Number of subjects: 812
Study 27486122 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation (2 RDAs daily for 6 months)
Number of subjects: 262
Study 27486122 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (2 RDAs daily for 6 months)
Number of subjects: 262
Study 27486122 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vitamin B12 and folic acid supplementation (2 RDAs daily for 6 months)
Number of subjects: 262
Study 27486122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 27486122 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (daily for 2 months)
Number of subjects: 262
Study 25920049 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 50
Study 25920049 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA
Number of subjects: 50
Study 25920049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24994725 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAX treatment criteria
Number of subjects: 150
Study 24994725 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone density testing
Number of subjects: 150
Study 24994725 — intervention group
Group type: COMPARATOR
Intervention: Osteoporosis treatment
Number of subjects: 150
Study 22611315 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-volume epinephrine (15 to 25 mL injection; Group 1, n = 50)
Number of subjects: 150
Study 22611315 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-volume epinephrine (30 to 40 mL injection; Group 2, n = 50)
Number of subjects: 150
Study 22611315 — intervention group
Group type: COMPARATOR
Intervention: Hemoclip (Group 3, n = 50)
Number of subjects: 150
Study 19577967 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior route of conduit transposition
Number of subjects: 49
Study 19577967 — intervention group
Group type: COMPARATOR
Intervention: Posterior route of conduit transposition
Number of subjects: 49
Study 17541049 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine, 60 mg/day
Number of subjects: 311